Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 1, 2005, Pages 434-437

  Conrads, Georg ^a,b   Citron, Diane M ^a   Goldstein, Ellie J C ^a  

^a R M ALDEN RESEARCH LABORATORY   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; DNA; GATIFLOXACIN; GLYCINE; LEUCINE; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; RIBOSOME RNA;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CAT; DNA DNA HYBRIDIZATION; DOG; FUSOBACTERIUM; FUSOBACTERIUM CANIFELINUM; GENE SEQUENCE; HEREDITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA GENE; SPECIES IDENTIFICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTI-INFECTIVE AGENTS; BASE SEQUENCE; CAT DISEASES; CATS; DNA GYRASE; DOG DISEASES; DOGS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; FUSOBACTERIUM; FUSOBACTERIUM INFECTIONS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA;

EID: 11244317560     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.1.434-437.2005     Document Type: Article

References (25)

1. Ackermann, G., Y. J. Tang-Feldman, R. Schaumann, J. P. Henderson, A. C. Rodloff, J. Silva, and S. H. Cohen. 2003. Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile. Clin. Microbiol. Infect. 9:526-530.
2. Bearden, D. T., and L. H. Danziger. 2001. Mechanism of action of and resistance to quinolones. Pharmacotherapy 21:224S-232S.
3. Conrads, G., D. Citron, R. Mutters, S. Jang, and E. Goldstein. 2004. Fusobacterium canifelinum sp. nov., from the oral cavity of cats and dogs. Syst. Appl. Microbiol. 27:407-413.
4. Conrads, G., M. C. Claros, D. M. Citron, K. L. Tyrrell, V. Merriam, and E. J. Goldstein. 2002. 16S-23S rDNA internal transcribed spacer sequences for analysis of the phylogenetic relationships among species of the genus Fusobacterium. Int. J. Syst. Evol. Microbiol. 52:493-499.
5. Dalhoff, A., and F. J. Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221.
6. Eguchi, T., Y. Shimizu, K. Furuhata, and M. Fukuyama. 2002. Antibacterial activity of new-quinolone and macrolide antibiotics against oral bacteria. Kansenshogaku Zasshi 76:939-945.
7. Goldstein, E. J., D. M. Citron, M. Hudspeth, S. Hunt Gerardo, and C. V. Merriam. 1998. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J. Antimicrob. Chemother. 41:391-396.
8. Goldstein, E. J., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. Fernandez. 2002. In vitro activities of the des-fluoro(6) quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections. Antimicrob. Agents Chemother. 46:866-870.
9. Goumas, P. D., S. S. Naxakis, D. A. Papavasiliou, E. D. Moschovakis, S. J. Tsintsos, and A. Skoutelis. 1997. Periapical abscesses: causal bacteria and antibiotic sensitivity. J. Chemother. 9:415-419.
10. Hecht, D. W., and J. R. Osmolski. 2003. Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates. Antimicrob. Agents Chemother. 47:910-916.
11. Hecht, D. W., and H. M. Wexler. 1996. In vitro susceptibility of anaerobes to quinolones in the United States. Clin. Infect. Dis. 23(Suppl. 1):S2-S8.
12. Ito, H., H. Yoshida, M. Bogaki-Shonai, T. Niga, H. Hattori, and S. Nakamura. 1994. Quinolone resistance mutations in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus. Antimicrob. Agents Chemother. 38:2014-2023.
13. King, A., J. Downes, C. E. Nord, and I. Phillips. 1999. Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic gram-negative bacilli in Europe. Clin. Microbiol. Infect. 5:404-416.
14. Kleinkauf, N., G. Ackermann, R. Schaumann, and A. C. Rodloff. 2001. Comparative in vitro activities of gemifloxacin, other quinolones, and non-quinolone antimicrobials against obligately anaerobic bacteria. Antimicrob. Agents Chemother. 45:1896-1899.
15. Krug, N. R., and J. G. Holt (ed.). 1984. Bergey's manual of systematic bacteriology. Williams & Wilkins, Baltimore, Md.
16. Miyamae, S., H. Nikaido, Y. Tanaka, and F. Yoshimura. 1998. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42:2119-2121.
17. National Committee for Clinical Laboratory Standards. 2000. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, 5th ed. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Nicholas, K. B., and H. B. J. Nicholas. 1997. GeneDoc: a tool for editing and annotation multiple sequence alignments. www.psc.edu/biomed/genedoc.
19. Nord, C. E. 1996. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin. Infect. Dis. 23(Suppl. 1):S15-S18.
20. Oh, H., and C. Edlund. 2003. Mechanism of quinolone resistance in anaerobic bacteria. Clin. Microbiol. Infect. 9:512-517.
21. Oh, H., N. El Amin, T. Davies, P. C. Appelbaum, and C. Edlund. 2001. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains. Antimicrob. Agents Chemother. 45:1977-1981.
22. Onodera, Y., and K. Sato. 1999. Molecular cloning of the gyrA and gyrB genes of Bacteroides fragilis encoding DNA gyrase. Antimicrob. Agents Chemother. 43:2423-2429.
23. Piddock, L. J. 1999. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58(Suppl. 2):11-18.
24. Stein, G. E., S. Schooley, K. L. Tyrrell, D. M. Citron, and E. J. Goldslein. 2003. Bactericidal activities of methoxyfluoroquinolones gatifloxacin and moxifloxacin against aerobic and anaerobic respiratory pathogens in serum. Antimicrob. Agents Chemother. 47:1308-1312.
25. Yoshida, H., M. Bogaki, M. Nakamura, L. M. Yamanaka, and S. Nakamura. 1991. Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob. Agents Chemother. 35:1647-1650.